Rabeprazole
- Generic Name
- Rabeprazole
- Brand Names
- Aciphex, Pariet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21N3O3S
- CAS Number
- 117976-89-3
- Unique Ingredient Identifier
- 32828355LL
- Background
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
- Indication
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
- Associated Conditions
- Duodenal Ulcer, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Non-erosive Reflux Esophagitis Disease (NERD), Vomiting, Zollinger-Ellison Syndrome, Develop NSAID-induced gastric ulcers, Erosive reflux esophagitis
- Associated Therapies
- -
Laryngopharyngeal Reflux and Proton Pump Inhibitor (PPI) Treatment
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2008-01-16
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 24
- Registration Number
- NCT00204698
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease
- Conditions
- Interventions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2011-10-05
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT00165672
Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole
- Conditions
- First Posted Date
- 2005-08-22
- Last Posted Date
- 2009-12-03
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 111
- Registration Number
- NCT00132496
- Locations
- 🇺🇸
Marshall University, Huntington, West Virginia, United States
🇺🇸Professional Clinical Research, Cadillac, Michigan, United States
🇺🇸University of Pediatrics, Mason, Ohio, United States
A Double-blind, Comparative Study in Patients With Gastric Ulcer to Evaluate the Efficacy of Combination Use of E0671 and Rabeprazole Sodium
- Conditions
- Interventions
- First Posted Date
- 2005-08-02
- Last Posted Date
- 2018-10-29
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 520
- Registration Number
- NCT00125736
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.